A structure-based, quantitative structure-activity relationship approach for predicting HLA-A*0201-restricted cytotoxic T lymphocyte epitopes

Chemical Biology and Drug Design

Volumn 69, Issue 1, 2007, Pages 56-67

  Zhou, Peng ^a   Tian, Feifei ^a   Li, Zhiliang ^a,b  

^a CHONGQING UNIVERSITY   (China)

^b State Key Laboratory of Chemo/Biosensing and Chemometrics   (China)

Author keywords

Computer aided vaccine design; Cytotoxic T lymphocyte epitope; Genetic algorithm partial least square regression; HLA A*0201; Structure based quantitative structure activity relationship

Indexed keywords

ALANYLALANYLALANYLLYSYLALANYLALANYLALANYLALANYLVALINE; ALANYLISOLEUCYLALANYLLYSYLALANYLALANYLALANYLALANYLVALINE; ALANYLISOLEUCYLISOLEUCYLASPARTYLPROLYLLEUCYLISOLEUCYLTYROSYLALANINE; ALANYLISOLEUCYLPHENYLALANYLGLUTAMINYLSERYLSERYLMETHIONYLTHREONYLLYSINE; ALANYLISOLEUCYLTYROSYLHISTIDYLPROLYLGLUTAMINYLGLUTAMINYLPHENYL ALANYLVALINE; ALANYLLEUCYLALANYLLYSYLALANYLALANYLALANYLALANYLALANINE; ALANYLLEUCYLALANYLLYSYLALANYLALANYLALANYLALANYLISOLEUCINE; ALANYLLEUCYLALANYLLYSYLALANYLALANYLALANYLALANYLLEUCINE; ALANYLLEUCYLALANYLLYSYLALANYLALANYLALANYLALANYLMETHIONINE; ALANYLLEUCYLALANYLLYSYLALANYLALANYLALANYLALANYLVALINE; ALANYLLEUCYLCYSTEINYLARGINYLTRYPTOPHYLGLYCYLLEUCYLLEUCYLLEUCINE; ALANYLLEUCYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; ALANYLLEUCYLTRYPTOPHYLGLYCYLPHENYLALANYLPHENYLALANYLPROLYLVALYLLEUCINE; ALANYLLEUCYLTRYPTOPHYLGLYCYLPHENYLALANYLVALYLPROLYLVALYLLEUCINE; ALANYLLEUCYLTRYPTOPHYLGLYCYLVALYLPHENYLALANYLPROLYLVALYLLEUCINE; EPITOPE; GLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCINE; HLA A ANTIGEN; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLVALYLGLYCYLISOLEUCYLLEUCINE; ISOLEUCYLLEUCYLLYSYLGLUTAMYLPROLYLVALYLHISTIDYLGLYCYLVALINE; ISOLEUCYLLEUCYLSERYLALANYLLEUCYLVALYLGLYCYLISOLEUCYLVALINE; LEUCYLLEUCYLPHENYLALANYLGLYCYLTYROSYLALANYLVALYLTYROSYLVALINE; LEUCYLLEUCYLPHENYLALANYLGLYCYLTYROSYLPROLYLARGINYLTYROSYLVALINE; LEUCYLLEUCYLPHENYLALANYLGLYCYLTYROSYLPROLYLVALYLALANYLVALINE; LEUCYLLEUCYLPHENYLALANYLGLYCYLTYROSYLPROLYLVALYLTYROSYLVALINE; PHENYLALANYLALANYLPROLYLGLYCYLPHENYLALANYLPHENYLALANYLPROLYLTYROSYL LEUCINE; PHENYLALANYLLEUCYLLYSYLGLUTAMYLPROLYLVALYLHISTIDYLGLYCYLVALINE; PHENYLALANYLLEUCYLTRYPTOPHYLGLYCYLPROLYLARGINYLALANYLLEUCYLVALINE; THREONYLLEUCYLTHREONYLSERYLCYSTEINYLASPARAGINYLTHREONYLSERYLVALINE; TYROSYLLEUCYLLYSYLGLUTAMYLPROLYLVALYLHISTIDYLGLYCYLVALINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CALCULATION; CHEMICAL BOND; COMPUTER AIDED DESIGN; CYTOTOXIC T LYMPHOCYTE; GENETIC ALGORITHM; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ALGORITHMS; BINDING SITES; ELECTROSTATICS; EPITOPES; HLA-A ANTIGENS; HYDROGEN BONDING; HYDROPHOBICITY; LIGANDS; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33847105892     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00472.x     Document Type: Article

References (47)

1. Yewdell J., Bennink J. (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol;17:51-81.
2. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., Eberlein T.Y. (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A;92:432-436.
3. Falk K., Rötzschke O., Stefanovic S., Jung G., Rammensee H.G. (1991) Allele specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature;351:290-296.
4. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., Sette A. (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A*0201 molecules. Cell;74:929-937.
5. Hagmann M. (2000) Computers aid vaccine design. Science;290:80-82.
6. Sette A. (2000) Tools of the trade in vaccine design. Science;290:2074-2075.
7. Pamer E.G., Harty J.T., Bevan M.J. (1991) Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature;353:852-855.
8. Hill A.V., Elvin J., Willis A.C., Aidoo M., Allsopp C.E., Gotch F.M., Gao X.M., Takiguchi M., Greenwood B.M., Townsend A.R. (1992) Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature;360:434-439.
9. Kast W.M., Brandt R.M., Sidney J., Drijfhout J.W., Kubo R.T., Grey H.M., Melief C.J., Sette A. (1994) Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol;152:3904-3912.
10. Kubo R.T., Sette A., Grey H.M., Appella E., Sakaguchi K., Zhu N.Z., Arnott D., Sherman N., Shabanowitz J., Michel H. (1994) Definition of specific peptide motifs for four major HLA-A alleles. J Immunol;152:3913-3925.
11. del Guercio M.F., Sidney J., Hermanson G., Perez C., Grey H.M., Kubo R.T., Sette A. (1995) Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol;154:685-693.
12. Altfeld M.A., Livingston B., Reshamwala N., Nguyen P.T., Addo M.M., Shea A., Newman M. et al. (2001) Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol;75:1301-1311.
13. Kawashima I., Tsai V., Southwood S., Takesako K., Sette A., Celis E. (1999) Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res;59:431-435.
14. Coyle A.J., Gutierrez-Ramos J.C. (2001) The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nat Immunol;2:203-209.
15. Sette A., Sidney J. (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol;10:478-482.
16. Parker K.C., Bednarek M.A., Coligan J.E. (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chain. J Immunol;152:163-175.
17. Sette A., Buus S., Appella E., Smith J.A., Chesnut R., Miles C., Colon S.M., Grey H.M. (1989) Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A;86:3296-3300.
18. Gulukota K., Sidney J., Sette A., DeLisi C. (1997) Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol;267:1258-1267.
19. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin U., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., Hammer J. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol;17:555-561.
20. Honeyman M.C., Brusic V., Stone N.L., Harrison L.C. (1998) Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol;16:966- 969.
21. Brusic V., Rudy G., Honeyman G., Hammer J., Harrison L. (1998) Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics;14:121-130.
22. Udaka K., Mamitsuka H., Nakaseko Y., Abe N. (2002) Empirical evaluation of a dynamic experiment design method for prediction of MHC class I-binding peptides. J Immunol;169:5744-5753.
23. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res;28:235-242.
24. Gao G.F., Tormo J., Gerth U.C., Wyer J.R., McMichael A.J., Stuart D.I., Bell J.I., Jones E.Y., Jakobsen B.K. (1997) Crystal structure of the complex between human CD8 alpha (alpha) and HLA-A2. Nature;387:630-634.
25. Madden D.R., Garboczi D.N., Wiley D.C. (1993) The antigenic identity of peptide/MHC complexes, a comparison of the conformations of five viral peptides presented by HLA-A2. Cell;75:693-708.
26. Collantes E.R., Dunn W.J. (1995) Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues. J Med Chem;38:2705-2713.
27. Goldsack D.E., Chalifoux R.C. (1973) Contribution of the free energy of mixing of hydrophobic side chains to the stability of the tertiary structure. J Theor Biol;39:645-651.
28. Fauchere J.L., Quarendon P., Kaetterer L. (1988) Estimating and representing hydrophobicity potential. J Mol Graph;6:203-206.
29. Kellogg G.E., Semus S.F., Abraham D.J. (1991) HINT - a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aided Mol Des;5:545-552.
30. Eisenberg D., McLachlan A.D. (1986) Solvation energy in protein folding and binding. Nature;319:199-203.
31. Ooi T., Oobatake M., Nmmethy G., Harold A., Scheraga H.A. (1987) Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. Proc Natl Acad Sci U S A;84:3086-3090.
32. Eisenberg E., Schwarz E., Komaromy M., Wall R. (1984) Analysis of membrane and surface protein sequences with the hydrophobic moment plot. J Mol Biol;179:125-142.
33. Hasel W., Hendrikson T.F., Still W.C. (1988) A rapid approximation to the solvent accessible surface areas of atoms. Tetrahed Comp Method;1:103-116.
34. Rose G.D., Geselowitz A.R., Lesser G.J., Lee R.H., Zehfus M.H. (1985) Hydrophobicity of amino acid residues in globular proteins. Science;229:834-838.
35. Gelin B.R., Karplus M. (1979) Side-chain torsional potentials: effect of dipeptide, protein, and solvent environment. Biochemistry;18:1256-1268.
36. Weiner S.J., Kollman P.A., Case D.A., Singh U.C., Ghio C., Alagona G., Profeta S., Weinerl P. (1984) A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc;106:765-784.
37. Vedani A., Dunitz J.D. (1985) Lone-pair directionality in hydrogen bond potential functions for molecular mechanics calculations: the inhibition of human carbonic anhydrase II by sulfonamides. J Am Chem Soc;107:7653-7658.
38. Fauchere J.L., Charton M., Kier L.B., Verloop A., Pliska V. (1988) Amino acid side chain parameters for correlation studies in biology and pharmacology. Int J Peptide Protein Res;32:269-278.
39. Blythe M.J., Doytchinova I.A., Flower D.R. (2002) JenPep: a database of quantitative functional peptide data for immunology. Bioinformatics;18:434-439.
40. Doytchinova I.A., Flower D.R. (2002) Physicochemical explanation of peptide binding to HLA-A*0201 major histocompatibility complex: a three-dimensional quantitative structure-activity relationship study. Proteins;48:505-518.
41. 2! J Mol Graph Mod;20:269-276.
42. Tropsha A., Gramatica P., Gombar V.K. (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci;22:69-77.
43. Wallace A.C., Laskowski R.A., Thornton J.M. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng;8:127-134.
44. Saper M.A., Bjorkman P.J. (1991) Refined structure of the human histocompatibility antigen HLA-A2 at 2.6Å resolution. J Mol Biol;219:277-319.
45. Madden D.R. (1995) The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol;13:587-622.
46. Sarobe P., Pendleton C.D., Akatsuka T.D., Engelhard V.H., Feinstone S.M., Berzofsky J.A. (1998) Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A 2.1 binding positions. J Clin Invest;102:1239-1248.
47. Kirksey T.J., Pogue-Caley R.R., Frelinger J.A., Collins E.J. (1999) The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes. J Biol Chem;274:37259-37264.